Moderna COO Juan Andres gets 7,898 stock options

Both award types have a 25% vesting milestone on November 5, 2027, followed by twelve equal quarterly installments.

Available on EDGAR 11/09/2026 - 04:39 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) Chief Operating Officer Juan Andres received 7,898 stock options and 16,955 restricted stock units on November 5, 2026. The options have an exercise price of $241.46 per share and expire November 5, 2036. For the options, 25% vests and becomes exercisable on November 5, 2027, with the remainder vesting in twelve equal quarterly installments thereafter. For the restricted stock units, 25% vests on that date, with the remainder vesting in twelve equal quarterly installments thereafter; each unit converts into common stock on a one-for-one basis.

Insider Trade Summary

Grant/Award: 24,853 shares

Grant/Award 2 txns

Insider Andres Juan

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	7,898	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	16,955	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,898 options (Direct); Restricted Stock Units — 16,955 units (Direct)

Footnotes (3)

1. F1. 25% of this option will vest and become exercisable on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
2. F2. Restricted stock units convert into common stock on a one-for-one basis.
3. F3. 25% of the shares subject to this restricted stock unit award will vest on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Key Figures

Award date: November 5, 2026 Stock options: 7,898 options Exercise price: $241.46 per share +5 more

8 metrics

Award date November 5, 2026 Date of both awards to Chief Operating Officer Juan Andres

Stock options 7,898 options Awarded to Chief Operating Officer Juan Andres

Exercise price $241.46 per share Stock options

Option expiration November 5, 2036 Expiration date of the stock options

Restricted stock units 16,955 units Awarded to Chief Operating Officer Juan Andres

Initial vesting 25% on November 5, 2027 Applies to both awards

Remaining vesting installments Twelve equal quarterly installments Applies to the remainder of both awards

Restricted stock unit conversion One-for-one basis Restricted stock units convert into common stock

Key Terms

Stock Option (Right to Buy), Restricted Stock Units, exercisable

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Restricted Stock Units financial

"Restricted Stock Units convert into common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercisable financial

"will vest and become exercisable on November 5, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Moderna (MRNA) COO Juan Andres receive?

On November 5, 2026, Chief Operating Officer Juan Andres received 7,898 stock options and 16,955 restricted stock units. The options have an exercise price of $241.46 per share and expire on November 5, 2036.

When do Juan Andres's MRNA awards vest?

For the option award, 25% vests and becomes exercisable on November 5, 2027, with the remainder vesting in twelve equal quarterly installments thereafter. For the restricted stock units, 25% vests on November 5, 2027, and the remainder vests in twelve equal quarterly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andres Juan

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$241.46	11/05/2026		A		7,898		(1)	11/05/2036	Common Stock	7,898	$0	7,898	D
Restricted Stock Units	(2)	11/05/2026		A		16,955		(3)	(3)	Common Stock	16,955	$0	16,955	D

Explanation of Responses:

1. 25% of this option will vest and become exercisable on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. 25% of the shares subject to this restricted stock unit award will vest on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

	/s/ James Dillon, as Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)